文献速递免疫规划卫生政策与健康促进

撒哈拉以南非洲八国引入轮状病毒疫苗的成本效益分析

Introducing rotavirus vaccine in eight sub-Saharan African countries: a cost-benefit analysis.
PubMed 文献 · Lancet Glob Health · 2021-01-01

结果显示所有八国引入轮状病毒疫苗的收益均超过成本,但赤道几内亚和加蓬的效益成本比相对较窄,需谨慎引入。

要点

  • 八国引入轮状病毒疫苗在建模期内收益均大于成本。

核心结论

  • 在八个撒哈拉以南非洲国家引入轮状病毒疫苗均具有成本效益,但赤道几内亚和加蓬需谨慎并采取严格措施以确保最佳健康收益和成本最小化。

研究设计与样本

  • 采用基于模拟的决策分析模型,对中非共和国、乍得、科摩罗、赤道几内亚、加蓬、几内亚、索马里和南苏丹1岁以下儿童随访至259周,进行成本效益分析。
  • 比较四种轮状病毒疫苗(Rotarix、Rotateq、Rotavac和Rotasiil)与不接种疫苗。
  • 次要分析包括成本效果分析和预算影响分析。

主要发现

  • Rotarix是所有Gavi eligible国家的最优选择;Rotasiil和Rotavac分别是赤道几内亚和加蓬的最优选择。

关键数值与推荐

  • 主要结局为伤残调整生命年避免数并转换为货币价值;主要经济评价指标为效益成本比(BCR)。

临床怎么用

  • 政策制定者在决定引入轮状病毒疫苗前,应将本疫苗的效益成本比与其他卫生保健项目的效益成本比进行比较。
  • 对于赤道几内亚和加蓬,需采用谨慎、务实且严格的措施以确保最佳健康收益和成本最小化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stimulated by the economic challenges faced by many sub-Saharan African countries and the changes in the rotavirus burden across these countries, this study aimed to inform the decision of health policy makers of eight sub-Saharan countries, who are yet to introduce the rotavirus vaccine as of Dec 31, 2020, on the health economic consequences of the introduction of the vaccine in terms of the costs and benefits. METHODS: We did a cost-benefit analysis using a simulation-based decision-analytic model for children aged younger than 1 year, who were followed up to 259 weeks, in the Central African Republic, Chad, Comoros, Equatorial Guinea, Gabon, Guinea, Somalia, and South Sudan. Data were collected and analysed between Jan 13, 2020, and Dec 11, 2020. Cost-effectiveness analysis and budget impact analysis were done as secondary analyses. Four rotavirus vaccinations (Rotarix, Rotateq, Rotavac, and Rotasiil) were compared with no vaccination. The primary outcome was disability-adjusted life-years averted, converted to monetary terms. The secondary outcomes include rotavirus gastroenteritis averted, and rotavirus vaccine-associated intussusception. The primary economic evaluation measure was the benefit-cost ratio (BCR). FINDINGS: For the modelling period, Jan 1, 2021, to Dec 31, 2030, we found that the benefits of introducing the rotavirus vaccine outweighed the costs in all eight countries, with Chad and the Central African Republic having the highest BCR of 19·42 and 11·36, respectively. Guinea had the lowest BCR of 3·26 amongst the Gavi-eligible countries. Equatorial Guinea and Gabon had a narrow BCR of 1·86 and 2·06, respectively. Rotarix was the optimal choice for all the Gavi-eligible countries; Rotasiil and Rotavac were the optimal choices for Equatorial Guinea and Gabon, respectively. INTERPRETATION: Introducing the rotavirus vaccine in all eight countries, but with caution in Equatorial Guinea and Gabon, would be worthwhile. With the narrow BCR for Equatorial Guinea and Gabon, cautious, pragmatic, and stringent measures need to be employed to ensure optimal health benefits and cost minimisation of the vaccine introduction. The final decision to introduce the rotavirus vaccine should be preceded by comparing its BCR to the BCRs of other health-care projects. FUNDING: Copenhagen Consensus Center and the Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Okafor CE, Ekwunife OI. Introducing rotavirus vaccine in eight sub-Saharan African countries: a cost-benefit analysis. Lancet Glob Health. 2021. PMID: 34297961. doi:10.1016/S2214-109X(21)00220-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。